文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

靶向前列腺特异性膜抗原(PSMA)的双特异性Fab缀合物,其可激活T细胞。

PSMA-targeted bispecific Fab conjugates that engage T cells.

作者信息

Patterson James T, Isaacson Jason, Kerwin Lisa, Atassi Ghazi, Duggal Rohit, Bresson Damien, Zhu Tong, Zhou Heyue, Fu Yanwen, Kaufmann Gunnar F

机构信息

Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, USA.

Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, USA.

出版信息

Bioorg Med Chem Lett. 2017 Dec 15;27(24):5490-5495. doi: 10.1016/j.bmcl.2017.09.065. Epub 2017 Oct 6.


DOI:10.1016/j.bmcl.2017.09.065
PMID:29126850
Abstract

Bioconjugate formats provide alternative strategies for antigen targeting with bispecific antibodies. Here, PSMA-targeted Fab conjugates were generated using different bispecific formats. Interchain disulfide bridging of an αCD3 Fab enabled installation of either the PSMA-targeting small molecule DUPA (SynFab) or the attachment of an αPSMA Fab (BisFab) by covalent linkage. Optimization of the reducing conditions was critical for selective interchain disulfide reduction and good bioconjugate yield. Activity of αPSMA/CD3 Fab conjugates was tested by in vitro cytotoxicity assays using prostate cancer cell lines. Both bispecific formats demonstrated excellent potency and antigen selectivity.

摘要

生物偶联物形式为双特异性抗体的抗原靶向提供了替代策略。在此,使用不同的双特异性形式生成了靶向前列腺特异性膜抗原(PSMA)的Fab缀合物。αCD3 Fab的链间二硫键桥接使得能够通过共价连接安装靶向PSMA的小分子二氟甲基鸟氨酸(DUPA)(合成Fab)或连接αPSMA Fab(双特异性Fab)。还原条件的优化对于选择性链间二硫键还原和良好的生物偶联物产率至关重要。使用前列腺癌细胞系通过体外细胞毒性试验测试了αPSMA/CD3 Fab缀合物的活性。两种双特异性形式均表现出优异的效力和抗原选择性。

相似文献

[1]
PSMA-targeted bispecific Fab conjugates that engage T cells.

Bioorg Med Chem Lett. 2017-12-15

[2]
Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single-chain diabody.

Prostate. 2010-10-13

[3]
A PSMA-Targeting CD3 Bispecific Antibody Induces Antitumor Responses that Are Enhanced by 4-1BB Costimulation.

Cancer Immunol Res. 2020-5

[4]
Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release.

J Immunother Cancer. 2021-6

[5]
Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens.

Mol Cancer Ther. 2012-10-5

[6]
Chemically generated IgG2 bispecific antibodies through disulfide bridging.

Bioorg Med Chem Lett. 2017-8-15

[7]
MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer.

Mol Cancer Ther. 2016-9

[8]
Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy.

Int J Nanomedicine. 2018-5-29

[9]
A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.

Clin Cancer Res. 2019-2-8

[10]
Targeting human prostate cancer with 111In-labeled D2B IgG, F(ab')2 and Fab fragments in nude mice with PSMA-expressing xenografts.

Contrast Media Mol Imaging. 2015

引用本文的文献

[1]
Facilitating high throughput bispecific antibody production and potential applications within biopharmaceutical discovery workflows.

MAbs. 2024

[2]
Chemical generation of checkpoint inhibitory T cell engagers for the treatment of cancer.

Nat Chem. 2023-11

[3]
The renaissance of chemically generated bispecific antibodies.

Nat Rev Chem. 2021-2

[4]
Identification of LAT/ZAP70 characterized immune subtypes of prostate cancer.

World J Urol. 2022-11

[5]
Chemical and Enzymatic Methods for Post-Translational Protein-Protein Conjugation.

J Am Chem Soc. 2022-8-17

[6]
Enabling the next steps in cancer immunotherapy: from antibody-based bispecifics to multispecifics, with an evolving role for bioconjugation chemistry.

RSC Chem Biol. 2021-10-22

[7]
A PSMA-targeted bispecific antibody for prostate cancer driven by a small-molecule targeting ligand.

Sci Adv. 2021-8

[8]
An IgG-based bispecific antibody for improved dual targeting in PSMA-positive cancer.

EMBO Mol Med. 2021-2-5

[9]
Revisiting Immunotherapy: A Focus on Prostate Cancer.

Cancer Res. 2020-2-17

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索